top of page

Philadelphia area based XyloCor is developing a gene therapy with the goal of helping to revascularize the heart for refractory angina patients

CEO Al Gianchetti explains that the company recently released final results from a phase 1/2 clinical trial and how XyloCor is set to begin a new study utilizing a catheter system that does not require open heart surgery for delivery.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

SAV_Logo_2024.png

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

bottom of page